𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Liver transplantation for non–hepatocellular carcinoma malignancies

✍ Scribed by Gregory J. Gores; Julie K. Heimbach; Charles B. Rosen

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
139 KB
Volume
16
Category
Article
ISSN
1527-6465

No coin nor oath required. For personal study only.

✦ Synopsis

Key Points

  1. Hepatic epithelioid hemangioendothelioma is a rare disease with a variable natural history; current data support liver transplantation for unresectable disease. 2. Anti-vascular endothelial cell growth factor therapy may change the approach to hepatic epithelioid hemangioendothelioma in the future. 3. The role of liver transplantation in the treatment of neuroendocrine tumors remains unclear; more data obtained by standardized approaches are needed for evidence-based decision making. 4. Liver transplantation is curative in highly selected patients with perihilar cholangiocarcinoma when it is combined with neoadjuvant therapy. Liver Transpl 16:S22-S25, 2010. V C 2010 AASLD.

📜 SIMILAR VOLUMES

Liver transplantation for non–hepatocell
Liver transplantation for non–hepatocellular carcinoma malignancy: Indications, limitations, and analysis of the current literature
✍ Eric J. Grossman; J. Michael Millis 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 497 KB

Orthotopic liver transplantation (OLT) is currently incorporated into the treatment regimens for specific nonhepatocellular malignancies. For patients suffering from early-stage, unresectable hilar cholangiocarcinoma (CCA), OLT preceded by neoadjuvant radiotherapy has the potential to readily achiev

Liver transplantation for hepatocellular
Liver transplantation for hepatocellular carcinoma
✍ Alan P. Venook 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 277 KB 👁 1 views

Background: Liver transplantation for unresectable hepatocellular carcinoma yields disappointing results. Most cases recur within 2 years, often in the transplanted liver. Methods: A combination of neoadjuvant doxorubicin and orthotopic liver transplantation was used in 20 patients with unresectable

Liver transplantation for hepatocellular
Liver transplantation for hepatocellular carcinoma: The MELD impact
✍ Pratima Sharma; Vijayan Balan; Jose L. Hernandez; Ann M. Harper; Erick B. Edward 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 1 views

The new allocation policy of the United Network of Organ Sharing (UNOS) based on the model for end-stage liver disease (MELD) gives candidates with stage T1 or stage T2 hepatocellular carcinoma (HCC) a priority MELD score beyond their degree of hepatic decompensation. The aim of this study was to de

Hepatocellular carcinoma: Sorafenib befo
Hepatocellular carcinoma: Sorafenib before liver transplantation?
✍ Alain Braillon 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 495 KB 👁 1 views

This study was partially supported by grants UBACYT M055 (Universidad de Buenos Aires) and PICT 06-124 (Agencia Nacional de Promocio´n Cien-tı´fica y Tecnolo´gica).